Clinical and functional outcomes of patients who experience partial response to citalopram: Secondary analysis of STAR*D

Journal of Psychiatric Practice

Volumn 20, Issue 3, 2014, Pages 178-187

  Dennehy, Ellen B ^a,b   Marangell, Lauren B ^c   Martinez, James ^d   Balasubramani, G K ^d   Wisniewski, Stephen R ^d  

^a ELI LILLY AND COMPANY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Depression; Function; Outcomes; Partial response; Remission; Sequenced treatment alternatives to relieve depression (STAR*D)

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEPRESSION; FEMALE; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH; MIDDLE AGED; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; QUICK INVENTORY OF DEPRESSIVE SYMPTOMS; REMISSION; SOCIAL ASPECT; TREATMENT RESPONSE; CONVALESCENCE; COST OF ILLNESS; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; DRUG RESISTANCE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL ADAPTATION; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED STATES;

ADULT; CITALOPRAM; COMORBIDITY; COST OF ILLNESS; DEMOGRAPHY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; SOCIAL SKILLS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84901480124     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000450317.76117.62     Document Type: Article

References (47)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder-Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. (Pubitemid 37432885
2. World Health Organization (WHO). The world health report 2001: Mental health: New understanding, new hope. Geneva: WHO; Oct 4, 2001 (available at www.who .int/whr/2001/en, accessed April 21, 2014
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000?. J Clin Psychiatry 2003; 64:1465-75
4. Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004;164:1197-1204 (Pubitemid 39030356
5. Trivedi M, Rush A, Wisniewski S, et al.; for the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006; 163:28-40
6. Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder. Depress Anxiety 2009;26:83-97
7. Kim J, Kim S, Stewart R, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: The CRESCEND study. Hum Psychopharmacol 2011; 26:41-50
8. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Rationale and design. Control Clin Trials 2004;25:119-42
9. Rush AJ, Bernstein IH, Trivedi MH, et al.; for the STAR*D Investigators Group. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial report. Biol Psychi-Atry 2006;59:493-501. (Pubitemid 43320536
10. Kennedy N, Paykel ES. Residual symptoms at remission from depression: Impact on long-Term outcome. J Affect Disord 2004;80;135-44. (Pubitemid 38597136
11. Papakostas GI. Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70(suppl 6):16-25
12. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 1995:25:1171-80
13. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108. (Pubitemid 28551779
14. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997; 45:5-18. (Pubitemid 27357459
15. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder, third edition. Arlington, VA: APA; 2010 (available at psychiatryonline.org/content.aspx?bookid=28 §ionid= 1667485, accessed April 22, 2014
16. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009:117:S26-S43
17. National Institute for Health and Clinical Excellence (NICE). Treatment and management of depression in adults, including adults with a chronic physical health problem. London: NICE; October 2009 (available at www.nice.org.uk/CG91, accessed April 22, 2014
18. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003; 26:457-94
19. Hamilton M. A rating scale for depression. J Neurol Neuro surg Psychiatry 1960;23:56-62
20. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-83. (Pubitemid 37289444
21. Rush AJ, Draemer HC, Sackeim HA, et al. Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 2006;31: 1841-53
22. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34:73-82. (Pubitemid 38139442
23. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986;18:65-87. (Pubitemid 16085767
24. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996;26:477-86. (Pubitemid 26142491
25. Kobak KA, Greist JH, Jefferson JW, et al. Computerized assessment of depression and anxiety over the telephone using interactive voice response. MD Computing 1999;16: 63-8
26. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231
27. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993;29:321-6. (Pubitemid 23311543
28. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: A simple measure of impairment in functioning. Br J Psychiatry 2002;180:461-4. (Pubitemid 34499343
29. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
30. Zimmerman M, Mattia JI. The reliability and validity of a screening questionnaire for 13 DSM-IV Axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. J Clin Psychiatry 1999;60:677-83. (Pubitemid 29503648
31. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: The Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry 2001;58: 787-94. (Pubitemid 32717805
32. Zimmerman M, Mattia JI. The Psychiatric Diagnostic Screening Questionnaire: Development, reliability and validity. Compr Psychiatry 2001;42:175-89. (Pubitemid 32410920
33. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-6
34. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: Remission and beyond. JAMA 2003;289:3152-60. (Pubitemid 37432891
35. Novick JS, Stewart JW, Wisniewski SR, et al.; for the STAR*D Investigators. Clinical and demographic features of atypical depression in outpatients with major depression: Preliminary findings from STAR*D. J Clin Psy chi-Atry 2005;66:1002-11. (Pubitemid 41191792
36. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004;34:1299-1308
37. Khan AY, Carrithers J, Preskorn SH, et al. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatry 2006;18:91-8. (Pubitemid 43879896
38. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011;31:180-6
39. Miller IW, Keitner GI, Schatzberg AF, et al. Psychosocial functioning before and after treatment with sertraline and imipramine. J Clin Psychiatry 1998;59:608-19
40. Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: Impact on functioning. Int Clin Psychopharmacol 2009;24:133-8
41. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22-33. (Pubitemid 36675445
42. Donohue JM, Pincus HA. Reducing the societal burden of depression: A review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007;25:7-24. (Pubitemid 46072365
43. Lenox-Smith A, Quail D, Martinez J, et al. Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: Post-hoc analysis findings from a European observational study. J Psychopharmacol 2012;(suppl 26)8:A48
44. Chang TE, Jing Y, Yeung AS, et al. Effect of communicating depression severity on physician prescribing patterns: Findings from the Clinical Outcomes in MEasurementbased Treatment (COMET) trial. Gen Hosp Psychiatry 2012:34:105-12
45. Hepner KA, Rowe M, Rost K, et al. The effect of adherence to practice guidelines on depression outcomes. Ann Intern Med 2007;147:320-9. (Pubitemid 351664559
46. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. Am J Psychiatry 2007;164:753-60. (Pubitemid 46808530
47. Rush AJ. STAR*D: What have we learned?. Am J Psychi-Atry 2007;164:2.